Table 1.
Adverse events in order of frequency
| Adverse events * | Topiramate (N = 896) N (%) |
| Paresthesia/numbness | 116 (12.9) |
| Nausea/vomiting | 56 (6.2) |
| Cognitive impairment | 48 (5.4) |
| Headache | 46 (5.1) |
| Dizziness | 45(5.0) |
| Sedation/drowsiness | 44 (4.9) |
| Fatigue | 38 (4.2) |
| Decreased appetite | 24 (2.7) |
| Frequent peristalsis | 20 (2.2) |
| Somnolence | 19 (2.1) |
| Blurred vision | 18 (2.0) |
| Slow memory | 16 (1.8) |
| Lack of concentration | 11 (1.2) |
| Influenza-like-symptoms | 10 (1.1) |
| Panic/anxiety | 9 (1.0) |
| Dysgeusia | 8 (0.9) |
| Dry mouth | 8 |
| Nervousness | 7 (0.8) |
| Rash | 7 |
| Ataxia | 7 |
| Insomnia | 7 |
| Constipation | 7 |
| Reduced libido | 5 (0.6) |
| Memory concerns | 5 |
| Dyspepsia | 5 |
| Unwanted weight loss | 4 (0.4) |
| Increased thirst | 4 |
| Word-finding difficulty | 4 |
| Impaired concentration | 4 |
| Tremor | 4 |
| Itching | 4 |
| Sweating | 3 (0.3) |
| Confusion | 3 |
| Slowed thinking | 3 |
| Psychosis | 3 |
| Slurred speech | 3 |
| Increased salivation | 3 |
| Sleep disturbance | 3 |
| Backache | 3 |
| Increased appetite | 2 (0.2) |
| Gastrointestinal disturbances | 2 |
| Agitation | 2 |
| Cold sensitivity | 2 |
| Worsening of symptoms | 2 |
| Increased libido | 2 |
| Amenorrhea | 1 (0.1) |
| Hematuria | 1 |
| Dysuria | 1 |
| Urticaria | 1 |
| Increased suicidality | 1 |
| Glaucoma | 1 |
| Water retention | 1 |
| Delirium | 1 |
| Grand mal seizures | 1 |
(*) From the studies reviewed only